StockNews.com downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a strong-buy rating to a buy ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) had its price target raised by HC Wainwright from $30.00 to $35.00 ...

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...

Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...

Catalyst Rises as Q2 Earnings & Revenues Beat Estimates Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) reported adjusted earnings of 56 cents per share for the second quarter of 2024, beating the ...

周三，Oppenheimer重申了对Catalyst Pharmaceutical Partners (NASDAQ:CPRX)股票的"跑赢大盘"评级，目标价保持在29.00美元。这一积极展望是在Catalyst Pharmaceutical宣布与TEVA就Firdapse仿制药营销达成交割协议之后做出的。